Pelacarsen Roll-over Extension Program (NCT06875973)
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
🩺 Plain-English Summary (8th-Grade Level)
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
Who can join: Review the eligibility criteria below.
Location: Parkway Medical Center — Birmingham, Alabama
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (97 Sites)
Showing the first 25 of 97 sites.
- Parkway Medical Center — Birmingham, Alabama
- Cardiology and Medicine Clinic PA — Little Rock, Arkansas
- National Heart Institute — Beverly Hills, California
- Hope Clinical Research — Canoga Park, California
- Valley Clinical Trials Inc — Covina, California
- NICRs Research Center — Garden Grove, California
- University of Calif Irvine Med Cntr — Irvine, California
- Long Beach Clinical Trials — Long Beach, California
- Angel City Research Inc — Los Angeles, California
- California Medical Research Associates Inc — Northridge, California
- Stanford Health Care — Stanford, California
- Excel Medical Clinical Trials LLC — Boca Raton, Florida
- C and A Clinical Trials — Cape Coral, Florida
- Proactive Clinical Research — Fort Lauderdale, Florida
- Proactive Clinical Research — Fort Lauderdale, Florida
- National Research Institute — Hialeah, Florida
- Sister Life Research Inc — Hialeah, Florida
- Zenith Clinical Research — Hollywood, Florida
- Columbus Clinical Services LLC — Miami, Florida
- Finlay Medical Research — Miami, Florida
- Infinite Clinical Research — Miami, Florida
- International Research Associates LLC — Miami, Florida
- Baptist Health South — Miami, Florida
- A&A Research Group Inc — Miami, Florida
- Inpatient Research Clinical LLC — Miami Lakes, Florida
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atherosclerotic Cardiovascular Disease
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Alexander City, Alabama
- A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease — Boston, Massachusetts
- VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease — Birmingham, Alabama
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Birmingham, Alabama
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Birmingham, Alabama
- Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE — Memphis, Tennessee
Explore by condition: All Atherosclerotic Cardiovascular Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.